WebNov 8, 2024 · The independent validation cohort included patients from the EMERGING-CTONG1103 trial, which was a multicenter phase II neoadjuvant study of patients with previously untreated EGFR-mutant stage ... WebJan 1, 2024 · In light of the growing need, the International Association of Lung Cancer (IASLC) has launched a multidisciplinary recommendation for the pathologic assessment of lung cancer resection specimens after neoadjuvant therapy to define pathologic response, including MPR or CPR, after neoadjuvant therapy in clinical trials and in routine practice ( …
Frontiers Dramatic response to neoadjuvant savolitinib in …
WebFeb 24, 2024 · The EMERGING-CTONG 1103 (ClinicalTrials.gov identifier: NCT01407822) was a multicentre (17 centres in China), open-label, phase II, randomised controlled trial … WebEMERGING-CTONG1103 showed neo-adjuvant/adjuvant erlotinib treatment significantly improved progression-free survival (PFS) vs standard doublet chemotherapy in patients (pts) with epidermal growth factor receptor ( EGFR) mutation-positive resectable stage IIIA (N2) non-small-cell lung cancer (NSCLC). can dairy cause bad breath
杨学宁 - 百度学术
WebEMERGING-CTONG1103 compared efficacy of neoadjuvant (and adjuvant) EGFR-TKI (erlotinib) with platinum-doublet chemotherapy (gemcitabine plus cisplatin). The primary endpoint of overall response rate (ORR) was not met for neoadjuvant erlotinib vs. chemotherapy (ORR 54.1% vs. 34.3%; P=0.092) in this cohort of 72 patients, and no … WebFeb 1, 2015 · When faced with stage IIIA-N2 NSCLC which is marginalized between operable and inoperable, CTONG1103 is quite emerging just as it’s called EMERGING to explore a brand new treatment strategy for this subsetting. Currently, the role of EGFR TKIs in perioperative early-stage NSCLC with EGFR activating mutations has not been … WebJan 20, 2024 · The EMERGING/CTONG1103 trial has been the largest published study investigating neoadjuvant treatment with a tyrosine kinase inhibitor ( 31 ). This was a Chinese, multicenter, phase 2, randomized controlled trial comparing erlotinib with chemotherapy (cisplatin plus gemcitabine) in patients with resectable, EGFR-mutated, … fishnet crop top men